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Abstract
We propose a multiple cohort expansion (MUCE) approach as a design or analysis method
for phase 1b multiple expansion cohort trials, which are novel first-in-human studies conducted
following phase 1a dose escalation. In a phase 1b expansion cohort trial, one or more doses of
a new investigational drug identified from phase 1a are tested for initial anti-tumor activities
in patients with different indications (cancer types and/or biomarker status). Each dose-
indication combination defines an arm, and patients are enrolled in parallel cohorts to all the
arms. The MUCE design is based on a class of Bayesian hierarchical models that adaptively
borrow information across arms. Specifically, we employ a latent probit model that allows
for different degrees of borrowing across doses and indications. Statistical inference is directly
based on the posterior probability of each arm being efficacious, facilitating the decision making
that decides which arm to select for further testing. The MUCE design also incorporates
interim looks, based on which the non-promising arms will be stopped early due to futility.
Through simulation studies, we show that MUCE exhibits superior operating characteristics.
We also compare the performance of MUCE with that of the Simon’s two-stage design and
existing Bayesian designs for multi-arm trials. To our knowledge, MUCE is the first Bayesian
method for phase 1b expansion cohort trials with multiple doses and indications.
∗Laiya Consulting, Inc.
†These authors contributed equally
‡Department of Public Health Sciences, The University of Chicago
§E-mail: yji@health.bsd.uchicago.edu
1
ar
X
iv
:2
00
6.
07
78
5v
1 
 [s
tat
.M
E]
  1
4 J
un
 20
20
1 Introduction
Phase 1b expansion cohort trials are a relative new type of studies to investigate the anti-tumor
effects of multiple doses of a new treatment in multiple indications. Here, indications can be different
cancer types according to histology, biomarker status, or both. Figure 1 is a stylized depiction of
a phase 1a/1b trial for a new drug: Part A refers the phase 1a dose escalation in which different
dose levels of the drug are investigated for safety; Part B is the phase 1b cohort expansion stage,
in which one or more candidate dose levels with reasonable safety profiles are selected for further
evaluation of efficacy. Both parts can be incorporated seamlessly in a single design or separated as
two different trials, depending on the practical situation for each drug development. In phase 1b,
patients with different indications are enrolled in parallel to these candidate doses, and their efficacy
outcomes are recorded. Since multiple doses and multiple indications may be tested, we refer to a
dose-indication combination as an “arm”, e.g., arms B1–B6 in Figure 1. At the end, the response
rate of an arm is estimated, based on which a go/no-go decision about further development of the
dose and indication is made.
In 2018, the US FDA released a draft guidance (FDA, 2018) that recommends the use of multiple
expansion cohort trials to expedite oncology drug development. A statistical design mentioned in
this draft guidance is the Simon’s two-stage design (Simon, 1989). The Simon’s two-stage design
provides trial sample size calculation and trial conduct for a binary endpoint (efficacy response/no
response) under the hypothesis test of H0k : pk ≤ pik0 versus H1k : pk ≥ pik1. Here, k is a specific
arm in the phase 1b trial, pk is the objective response rate (ORR) in arm k, pik0 is the reference
response rate, such as the rate under the standard of care (SOC), and pik1 is the target response
rate, with which the drug is regarded superior. Here, objective response refers to partial or complete
response, according to the RECIST (ref) guideline. (Note)1 The Simon’s two-stage design proceeds
as follows: in the first stage, n1 patients are enrolled, and the trial is stopped if r1 or fewer patients
respond. Otherwise, additional (N − n1) patients are enrolled in the second stage, and the drug is
considered promising and H0 rejected if more than r patients (including those from the first stage)
respond. The tuple (r1, n1, r, N) is determined based on the desired control of frequentist type I and
II error rates and certain optimality conditions, such as minimizing the expected sample size. The
1Need RECIST reference.
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Figure 1: A stylized depiction of a two-part phase 1 study. Part A is phase 1a dose escalation
and Part B phase 1b cohort expansion. In the dose-escalation stage, four candidate dose levels are
investigated for safety, and dose level 3 is identified as the maximum tolerated dose (MTD), i.e., the
highest dose with tolerable side effects. In the cohort-expansion stage, the MTD and the dose below
(dose level 2) are considered for further investigation. Patients with three different indications are
enrolled in parallel for both doses. This leads to a total of six cohorts, cohorts B1–B3 for dose level
3 and cohorts B4–B6 for dose level 2.
Simon’s two-stage design is appealing for single-arm studies, since the design can limit the number
of patients exposed to an inefficacious drug. To apply the Simon’s two-stage design to multi-arm
trials, one could treat each arm as a separate study, and the tuple (r1, n1, r, N) is determined for
each arm under arm-specific type I and type II error rates. The BRAF-V600 study in Hyman
et al. (2015) is an example of using the Simon’s two-stage design in a multi-arm trial. However,
the Simon’s two-stage design was developed for single-arm trials and may not be the most efficient
design for multi-arm trials (including multiple expansion cohort trials) for at least two reasons.
First, an important rationale to include multiple arms (e.g., multiple doses and indications) into a
single study is that the treatment effects in some arms may provide information about the treatment
effects in other arms. Therefore, it is desirable to borrow information across arms when we design
the trial and perform data analysis. Second, in a multi-arm trial, applying the Simon’s two-stage
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design independently to each arm does not take into account the family-wise type I error rate
(FWER). For example, consider a trial with 4 arms. Suppose each arm is designed with a type I
error rate of 0.1, then the FWER can be as high as 1− (1− 0.1)4 = 0.35, which means that with a
probability of 0.35 an inefficacious arm may be recommended for further development. Of course,
to guarantee that the FWER is no higher than α, one could apply the Bonferroni correction and
require the type I error rate for each arm to be no higher than α/K, where K is the number of
arms. However, that may result in a large sample size for early-phase trials.
Several Bayesian designs have been proposed for multi-arm clinical trials, such as Thall et al.
(2003), Berry et al. (2013), Neuenschwander et al. (2016), Simon et al. (2016), Liu et al. (2017),
Cunanan et al. (2017), Chu and Yuan (2018a), Chu and Yuan (2018b), Hobbs and Landin (2018) and
Psioda et al. (2019), among others. A majority of these designs make use of Bayesian hierarchical
models to borrow information across arms and increase statistical efficiency. Most of these designs
are developed for basket trials (Heinrich et al., 2008, Menis et al., 2014, Hyman et al., 2015), which
evaluate a new treatment in multiple indications (without the notion of multiple doses). In this
paper, we extend the idea of existing Bayesian designs for multi-arm trials and develop a design
specifically for multiple expansion cohort trials. The proposed design is called MUCE, which stands
for multiple cohort expansion. A unique feature of multiple expansion cohort trials is that they could
have a two-dimensional dependency structure across doses and indications. For example in Figure
1, when two doses are expanded in three indications, dependence in both doses and indications may
affect model performance.
A motivating example. We introduce a case study that motivates the MUCE design. Consider
a seamless phase 1a/1b trial that evaluates the safety and efficacy of a bispecific monoclonal cancer
drug. In phase 1a, five doses are tested for safety. The endpoint is dose-limiting toxicity (DLT).
Phase 1a is guided by the i3+3 design (Liu et al., 2019), which employs a set of rules to make
dose-escalation decisions. The maximum tolerated dose (MTD) will be identified from phase 1a
dose finding. Up to three doses, none higher than the MTD, will be considered for expansion in the
phase 1b study, and four different indications based on histology will be considered. This leads to
a maximum of 12 arms, each with a unique dose-indication combination. The phase 1b endpoint is
objective response. The ORR of each arm is compared to a historical rate. Specifically, for arm k,
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we intend to test the null hypothesis H0k : pk ≤ pik0 versus the alternative hypothesis H1k : pk > pik0,
with pik0 = 0.2 being the historical response rate for all arms. The Simon’s two-stage design may
not be the best choice for this trial. To see this, consider applying the Simon’s two-stage design
independently to each arm. In the extreme case, 12 arms will be expanded in phase 1b. Then, the
Simon’s two-stage design with an arm-specific type I error rate of α = 0.1 would result in a FWER
of 1 − (1 − 0.1)12 = 0.72. Apparently, this is not acceptable since such a type I error rate would
render a great risk for downstream clinical development. In addition, the trial budget only allows
about 10 patients per arm, making it difficult to use the Simon’s two-stage design with decent
power. It is important to borrow information to allow reasonable power. We will present numerical
results for this trial based on the MUCE design later.
Motivated by the case study, we develop the MUCE design to power multi-dose/indication
expansion cohort trials. The MUCE design is based on a class of Bayesian hierarchical models that
allows different degrees of borrowing across the two dimensions – doses and indications. For example,
the drug may perform more similarly across different doses than across different indications. This
is different from existing Bayesian designs for multi-arm trials, which are developed aiming for one-
dimensional borrowing. In additin, the MUCE design directly makes inference based on the posterior
probability of the alternative hypothesis Pr(H1k | Data). Through a Bayesian hierarchical models
including prior probabilities of the hypotheses, we follow the argument in Scott and Berger (2010)
to realize Bayesian multiplicity control. We will demonstrate through simulation studies that the
MUCE design has desirable operating characteristics.
The remainder of the paper is organized as follows. In Section 2, we provide a brief review of
existing Bayesian designs for multi-arm trials. In Section 3, we propose the probability model and
the decision rules for the MUCE design. In Section 4, we evaluate the operating characteristics of
the proposed MUCE design and present simulation results. The paper concludes with a discussion
in Section 5.
2 Review of Bayesian Designs for Multi-arm Trials
In this section, we provide an overview of existing Bayesian designs for multi-arm trials. Let K
denote the number of arms in the trial. For example, in a multiple expansion cohort trial, K
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is the number of arms, i.e., dose-indication combinations; in a basket trial, K is the number of
indications. Let nk and yk denote the number of patients and responders in arm k, respectively.
Here, a responder refers to a cancer patient who has a beneficial outcome after the treatment, where
the beneficial outcome is usually defined based on tumor shrinkage or some meaningful anti-tumor
activities (e.g., those in Eisenhauer et al., 2009). Denote by pk the true and unknown response rate
for arm k. A natural sampling model for yk is the binomial model, yk | pk ∼ Bin(nk, pk).
Berry et al. (2013) propose a Bayesian hierarchical model (BBHM) which borrows strength across
different arms. For each arm k, BBHM considers a hypothesis test:
H0k : pk ≤ pik0 versus H1k : pk ≥ pik1,
where pik0 and pik1 are the reference and target response rates for arm k, respectively. Let θk =
logit(pk) − logit(pik1) denote the log-odds of the response rate including an adjustment for the
targeted rate pik1, where logit(x) = log[x/(1 − x)]. BBHM models the θk’s via a shrinkage prior
given by
θk | θ, σ2 iid∼ N(θ, σ2), k = 1, . . . , K. (1)
The hyperparameters θ and σ2 are given conjugate hyperpriors,
θ ∼ N(θ0, σ20), and σ2 ∼ Inv-Gamma(α0, β0).
This prior construction assumes that the θk’s across different arms are exchangeable and are shrunk
toward a shared mean θ, which enables borrowing information across the K arms. The degree of
borrowing is determined by the value of σ2. The smaller the σ2, the stronger the borrowing. On
one extreme, when σ2 = 0, all the θk’s are equal, resulting in full shrinkage. On the other extreme,
when σ2 goes to infinity, the degree of borrowing goes to zero.
The BBHM design incorporates interim analyses for futility stopping. Specifically, each interim
analysis occurs after a pre-specified number of patients are enrolled. If
Pr
(
pk >
pik0 + pik1
2
| Interim data
)
< φ1, (2)
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enrollment to arm k is stopped for futility; otherwise, enrollment to arm k continues until the next
interim analysis or the end of the trial. At the end of the trial, a final analysis is conducted, and
arm k is declared efficacious and promising for further study if
Pr(pk > pik0 | Final data) > φ2. (3)
Here, φ1 and φ2 are tuning parameters, which may be determined through simulation studies to
generate desirable frequentist operating characteristics.
BBHM design shows superior power when most arms are truly efficacious. The cost is the inflated
frequentist type I error rates for non-promising arms, if the models are configured to borrow across
all the arms. See, e.g., Neuenschwander et al. (2016), Chu and Yuan (2018a) and Chu and Yuan
(2018b) for discussions. Several alternative methods have been proposed, attempting to mitigate
the issue. Neuenschwander et al. (2016) propose the exchangeability-nonexchangeability (EXNEX)
design, which models the θk’s in Equation (1) with a mixture distribution,
θk ∼
C∑
c=1
wkcN(θEX,c, σ
2
EX,c) + wk0N(θNEX,k, σ
2
NEX,k).
In other words, with probability wkc, θk belongs to an exchangeability (EX) component c, and
with probability wk0, θk belongs to a nonexchangeability (NEX) component;
∑C
c=0wkc = 1. The
parameters of the EX components, θEX,c and σEX,c, are shared across arms within component c. In
contrast, the parameters of the NEX components, θNEX,k and σNEX,k, are arm-specific. The number
of EX components C and the weights of the components wk = (wk1, . . . , wkC , wk0) are prespecified.
The authors recommend as a default setting that the same NEX components and mixture weights
are used for all arms, i.e., θNEX,1 = . . . = θNEX,K = θNEX, σ
2
NEX,1 = . . . = σ
2
NEX,K = σ
2
NEX,
and w1 = . . . = wK = w. The NEX variance σ
2
NEX should be chosen large to ensure a good
performance. Interestingly, this default setting collapses all the nonexchangeable components into
a single component, effectively rendering the model “exchangeable”. However, the use of the mixture
model in EXNEX reduces the extent of borrowing across arms thus leads to less type I error inflation
compared to BBHM. The original EXNEX design does not have a futility stopping rule, but the same
rule as in Equation (2) may be included.
7
Chu and Yuan (2018a) propose a calibrated Bayesian hierarchical model (CBHM), which uses
an empirical Bayes estimate of σ2 in Equation (1) rather than placing a prior on it. This calibration
process results in more conservative estimation of σ2 compared to BBHM when the treatment effects
in different arms are less homogeneous, leading to less borrowing and type I error inflation. The
CBHM design has the same decision rules for futility stopping and declaring efficacy as the BBHM
design.
3 The MUCE Design
The MUCE design takes a slightly different angle. Instead of using the posterior credible interval
of the estimated response rate (Equations 2 and 3) for decision and inference, in MUCE we propose
a hierarchical model incorporating the hypotheses as a parameter, i.e., Bayesian hypothesis testing.
Also, to exploit the data structure in multiple expansion cohort trials, we construct a latent probit
model that allows different degrees of borrowing across doses and indications. This will be more
clear in the upcoming discussion.
3.1 Probability Model
Consider a phase 1b trial that evaluates J different dose levels of a new drug in I different indications.
Let (i, j) denote the arm for indication i and dose level j, i = 1, . . . , I, j = 1, . . . , J . The total
number of arms is K = I × J . Suppose nij patients have been treated in arm (i, j), and yij of them
are responders. Let pij denote the true and unknown response rate for the arm (i, j). We assume
yij follows a binomial distribution, yij | pij ∼ Bin(nij, pij). Whether dose level j is efficacious for
indication i can be examined by the following hypothesis test:
H0,ij : pij ≤ pii0 versus H1,ij : pij > pii0, (4)
where pii0 is the reference response rate for indication i. For simplicity, we do not separately consider
a target response rate pii1 as in the Simon’s two-stage and BBHM designs. This is because only
the reference response rate is used for declaring treatment efficacy in the final analysis for all the
existing Bayesian designs (Equation 3).
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Under a formal Bayesian testing framework for (4), let λij be a binary and random indicator
of the hypothesis, such that λij = 0 (or 1) represents that hypothesis H0,ij (or H1,ij) is true. We
formally construct a hierarchical model treating λij as a model parameter and perform inference
on λij directly. In the first step, we build a prior model for pij under each hypothesis. Similar to
BBHM, we consider the logit transformation of pij, θij = logit(pij). The null hypothesis pij ≤ pii0
is equivalent to θij ≤ θi0, and the alternative hypothesis is equivalent to θij > θi0, where θi0 =
logit(pii0). Conditional on λij, we assume
θij | λij = 0 ∼ Trunc-Cauchy(θi0, γ; (−∞, θi0]),
θij | λij = 1 ∼ Trunc-Cauchy(θi0, γ; (θi0,∞)),
where Trunc-Cauchy(θ, γ;A) denotes a Cauchy distribution with location θ and scale γ truncated
within interval A. The use of the Cauchy distribution priors follows Gelman et al. (2008) due to its
heavy tail, thus inducing large prior variability and less prior influence.
In the second step, we construct prior models for the probabilities of the hypotheses, Pr(λij = 1)
and Pr(λij = 0). To borrow strength across dose levels and indications, we construct a hierarchical
prior model for λij. A natural and conventional Bayesian approach is to impose a common prior for
the probability of {λij = 1} (e.g., similar to the prior in Equation 1), which shrinks the probabilities
to a common value. To better exploit the data structure in multiple expansion cohort trials, we
propose to differentiate the borrowing strength from two factors: dose and indication. For example,
two arms with the same indication or dose might exhibit more similar treatment effects than two
arms with different indications and doses. To achieve this, we use a latent probit two-way ANOVA
prior. Let Zij be a latent Gaussian random variable, and λij = I(Zij ≥ 0), where I(·) is an indicator
function. Hence Pr(λij = 1) = Pr(Zij ≥ 0). We model
Zij ∼ N(ξi + ηj, σ20).
Here, E(Zij) = ξi + ηj, in which ξi characterizes the effect of indication i and ηj of dose j. The
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indication-specific effects and dose-specific effects are then separately modeled by common priors,
ξi | ξ0, σξ iid∼ N(ξ0, σ2ξ ), and ηj | η0, ση iid∼ N(η0, σ2η).
Lastly, we put hyperpriors on ξ0 and η0, ξ0 ∼ N(µξ0 , σ2ξ0) and η0 ∼ N(µη0 , σ2η0).
The entire hierarchical models are summarized in the following display:
Likelihood: yij | nij, pij ∼ Bin(nij, pij);
Transformation: θij = logit(pij), θi0 = logit(pii0);
Prior for (θij | λij): θij | λij = 0 ∼ Trunc-Cauchy(θi0, γ; (−∞, θi0]),
θij | λij = 1 ∼ Trunc-Cauchy(θi0, γ; (θi0,∞));
Prior for λij: λij =
0, if Zij < 0,1, if Zij ≥ 0; (5)
Latent probit regression: Zij | ξi, ηj, σ20 ∼ N(ξi + ηj, σ20);
Indication-specific effects: ξi | ξ0, σ2ξ ∼ N(ξ0, σ2ξ );
Dose-specific effects: ηj | η0, σ2η ∼ N(η0, σ2η);
Hyperpriors: ξ0 | µξ0 , σ2ξ0 ∼ N(µξ0 , σ2ξ0),
η0 | µη0 , σ2η0 ∼ N(µη0 , σ2η0).
The values of the hyperparameters γ, µξ0 , µη0 , σ
2
0, σ
2
ξ , σ
2
η, σ
2
ξ0
and σ2η0 are fixed, and the specification
of these hyperparameters will be discussed next.
Under the proposed hierarchical model, different Zij’s are a priori correlated, thus the model
borrows information across arms. To see this, consider the prior correlations of (Zij, Zi′j′) in the
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following three cases:
(I) Same indication (i = i′): Corr(Zij, Zij′) =
σ2ξ + (σ
2
ξ0
+ σ2η0)
σ20 + σ
2
ξ + σ
2
ξ0
+ σ2η + σ
2
η0
,
(II) Same dose (j = j′): Corr(Zij, Zi′j) =
σ2η + (σ
2
ξ0
+ σ2η0)
σ20 + σ
2
ξ + σ
2
ξ0
+ σ2η + σ
2
η0
, (6)
(III) Different indication & dose: Corr(Zij, Zi′j′) =
(σ2ξ0 + σ
2
η0
)
σ20 + σ
2
ξ + σ
2
ξ0
+ σ2η + σ
2
η0
.
We can see that the degree of borrowing is determined by the relative magnitude of σ20, σ
2
ξ , σ
2
η,
σ2ξ0 and σ
2
η0
, with correlation being the smallest for case (III). For the other two cases, if σ2ξ > σ
2
η
(or σ2ξ < σ
2
η), the correlation for case (I) is larger (or smaller) than the correlation for case (II),
respectively. By default, we set σ20 = 1. We will show sensitivity analyses in which desirable degree
of borrowing could be realized with different choices of variance values.
Lastly, the values of µξ0 and µη0 affect the prior probability of Pr(λij = 1). In particular,
more negative values of µξ0 and µη0 make the prior Pr(λij = 1) smaller, and hence the posterior
Pr(λij = 1 | Data) is also smaller given the same likelihood. We will show that this feature is useful
in calibrating MUCE to make it conservative or not in practice, thereby controling type I error.
3.2 Posterior inference
Let θ, Z, ξ, η be the set of all θij’s, Zij’s, ξi’s and ηj’s, respectively. The joint posterior distribution
of the parameters is given by
p(θ,Z, ξ,η, ξ0, η0 | y,n) ∝
{∏
i,j
f(yij | nij, θij) · pi(θij | Zij) · pi(Zij | ξi, ηj)
}
·{∏
i
pi(ξi | ξ0)
}
·
{∏
j
pi(ηj | η0)
}
· pi(ξ0) · pi(η0),
where f(yij | nij, θij) = [eθij/(1 + eθij)]yij · [1/(1 + eθij)]nij−yij , and pi(·) represents the corresponding
prior densities as in Equation (5). Posterior samples of the unknown parameters,
{θ(r),Z(r), ξ(r),η(r), ξ0(r), η0(r); r = 1, . . . , R},
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are obtained through Markov chain Monte Carlo (MCMC) simulation, where R denotes the maxi-
mum number of MCMC iterations. The MCMC simulation follows standard Gibbs and Metropolis-
Hastings steps, the detail of which is omitted.
3.3 Proposed Trial Design
Based on the probability model in Section 3.1, we propose the MUCE design for multiple expansion
cohort trials. The MUCE design without interim looks can be derived based on the following logic.
We enroll nij patients to arm (i, j), and declare the arm promising if
Pr(λij = 1 | D) > φ2
or not promising if Pr(λij = 1 | D) < φ1. Here, D = {(nij, yij); i = 1, . . . , I, j = 1, . . . , J} denotes
the observed data at the end of the trial, where yij is the number of responders in arm (i, j). The
posterior probability of H1,ij being true (i.e., λij = 1) can be approximated from the posterior
MCMC samples,
Pr(λij = 1 | D) ≈ 1
R
R∑
r=1
I(Z
(r)
ij ≥ 0).
Recall that {Z(r)ij ; r = 1, . . . , R} denotes R posterior samples of Zij. From a Bayesian perspective,
cutoff φ2 is specified so that (1− φ2) gives a desired posterior probability of null (PPN) when arm
(i, j) is considered promising, i.e., a false positive decision is made. For example, φ2 = 0.9 gives a
PPN of 0.1 as the upper bound for making a false positive decision using the Bayesian inference.
Similarly, the value of φ1 provides the upper bound of the posterior probability of alternative
(PPA). For example, φ1 = 0.3 gives a small PPA and indicates a small probability of making a false
negative decision given the data and the MUCE model. After φ2 and φ1 are specified, the sample
sizes {nij; i = 1, . . . , I, j = 1, . . . , J} are decided based on simulation so that desirable frequentist
type I/II error rates are achieved.
Once φ2, φ1 and {nij} are decided, one can add futility interim looks to the MUCE design.
Suppose L(≥ 1) interim looks are planned, and interim analysis l is conducted after nlij patients
have been enrolled in arm (i, j), where nlij < nij. Let Dl = {(nlij, ylij); i = 1, . . . , I, j = 1, . . . , J}
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denote the observed data at interim analysis l, where ylij is the number of responders among the n
l
ij
patients. At each interim analysis, arm (i, j) is stopped early for futility if Pr(λij = 1 | Dl) < φ1.
See Box 1. Note that the maximum sample sizes {nij} may be recalibrated if interim looks are
planned, again based on simulation.
Box 1: The MUCE design with L futility interim looks.
0. Let l = 1.
1. After nlij patients have been enrolled in arm (i, j), calculate Pr(λij = 1 | Dl). If Pr(λij = 1 |
Dl) < φ1, stop patient accrual in this arm for futility.
2. If patient accrual in all arms has been stopped, stop the trial. Otherwise, let l = l + 1.
(a) If l ≤ L, go back to step 1;
(b) Otherwise, enroll patients until the maximum sample size nij is reached for arm (i, j).
Evaluate each arm based on the final observed data. If Pr(λij = 1 | D) > φ2, declare
arm (i, j) promising at the end of the trial.
4 Results
4.1 Two Trial Examples
In this section, we illustrate the application of the MUCE design through two hypothetical trials,
denoted as trial examples I and II. These examples are based on a simplified version of the motivating
example described in Section 1. In both examples, one dose is expanded in four indications (i.e.,
J = 1 and I = 4), with the reference response rate pii0 = 20% for all indications. We set φ1 = 0.3
as the threshold for futility stopping at each interim analysis and φ2 = 0.9 for declaring treatment
efficacy at the final analysis. Recall that φ1 represents the upper bound of the PPA when a negative
decision is made, and (1− φ2) represents the upper bound of the PPN when a positive decision is
made. For simplicity, we set the maximum sample size to be 29 per arm, which is chosen to match
the sample size of the Simon’s two-stage design with a type I error rate of 0.1, a type II error rate of
0.3, a reference response rate of pii0 = 20%, and a target response rate of pii1 = 35%. In practice, the
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maximum sample size may be chosen based on simulation to attain desirable frequentist properties.
Two interim looks for futility stopping are conducted after the responses of 10 and 20 patients have
been evaluated in every arm, respectively. Through these two trial examples, we will show the effect
of borrowing across arms and the benefit of futility stopping.
We apply MUCE under the following three hyperparameter settings:
1. Setting 1: γ = 2.5, µξ0 = µη0 = 0, and σ
2
0 = σ
2
ξ = σ
2
η = σ
2
ξ0
= σ2η0 = 1;
2. Setting 2: Same as Setting 1 except σ2ξ0 = σ
2
η0
= 32;
3. Setting 3: Same as Setting 1 except µξ0 = µη0 = −3.
Here, Setting 1 is the default hyperparameter setting. Setting 2 imposes more information borrowing
compared to Setting 1, as it increases the correlation of Zij across different arms (see Equation 6).
Setting 3 places a lower prior probability for H1,ij, which makes it easier to stop an arm early due
to futility and more difficult to declare treatment efficacy at the end of the trial.
Table 1 shows the simulated data for trial example I and inference based on MUCE under the
three hyperparameter settings. At the first interim look, respectively 1, 2, 3, and 4 responders are
reported among the first 10 enrolled patients. Under Setting 1, the posterior probability of H1,ij
is greater than φ1 = 0.3 for all arms, and therefore patient accrual continues in all arms. The
estimated response rates under MUCE show the effect of “borrowing”, as the smaller observed
response rates in arms 1 and 4 are up-shifted and those in arms 2 and 3 are down-shifted. See
Figure 2 for an illustration. Setting 2 leads to stronger borrowing, which can be seen from the
greater degree of shrinkage of the estimated response rates compared to that under Setting 1.
Again, no arm is stopped early for futility. Setting 3 leads to lower estimated response rates and
posterior probabilities of H1,ij’s, because it assumes a lower prior probability of H1,ij by imposing
negative µξ0 and µη0 values in the latent probit regression. As a result, the posterior probabilities
of H1,ij’s are also lower, and arm 1 is stopped early due to futility. In other words, negative values
of µξ0 and µη0 lead to more conservative decisions.
The second interim analysis occurs after 20 patients have been assessed for response in every
arm. Again, under Setting 1, the futility stopping boundary is not crossed, and the trial continues
with all four arms. At the end of the trial, 6, 13, 11 and 20 responders are observed in arms
1, 2, 3 and 4, respectively. The posterior probabilities of H1,ij for arms 2, 3 and 4 are over the
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Figure 2: An illustration of the effect of information borrowing under MUCE. The dotted circles
represent the observed/raw response rates in the four arms. The solid arrows show the shrinkage
direction of the estimated response rates based on MUCE. In this example, the estimated response
rates in the four arms are shrunk toward the overall mean, with smaller observed response rates in
arms 1 and 4 up-shifted and those in arms 2 and 3 down-shifted.
Table 1: Trial example I under the MUCE design. “Est. p” denotes the estimated response rate,
and “Prob. H1” denotes the posterior probability of the alternative hypothesis, i.e., Pr(λij = 1 | D).
The bold values indicate the arms that are declared promising at the final analysis. The values in
square brackets indicate the arms that are stopped early due to futility. The values in parentheses
indicate that the interim data are carried forward for the subsequent analyses after the arms are
stopped early.
Interim 1 Interim 2 Final Analysis
arm 1 2 3 4 1 2 3 4 1 2 3 4
n 10 10 10 10 20 20 20 20 29 29 29 29
y 1 5 6 3 4 10 9 8 6 13 11 10
y/n 0.1 0.5 0.6 0.3 0.2 0.5 0.45 0.4 0.21 0.45 0.38 0.34
Est. p
Set. 1 0.139 0.473 0.572 0.304 0.24 0.483 0.435 0.388 0.237 0.437 0.371 0.34
Set. 2 0.199 0.478 0.574 0.326 0.258 0.482 0.437 0.387 0.254 0.438 0.368 0.34
Set. 3 [0.076] 0.361 0.462 0.198 (0.082) 0.479 0.426 0.37 (0.084) 0.431 0.355 0.314
Prob. H1
Set. 1 0.482 0.987 0.997 0.862 0.814 0.999 0.998 0.993 0.828 1.000 0.995 0.987
Set. 2 0.747 0.994 0.999 0.944 0.930 1.000 0.999 0.997 0.945 1.000 0.999 0.997
Set. 3 [0.076] 0.687 0.762 0.37 (0.144) 0.987 0.969 0.923 (0.130) 0.977 0.932 0.864
efficacy threshold φ2 = 0.9, and the dose is considered promising in these arms. Under Setting
2, the posterior probability of H1,ij is higher in all arms due to stronger borrowing compared to
that under Setting 1, and the dose is considered promising in all arms. Under Setting 3, due to
the lower prior probability of H1,ij, the posterior probability of H1,ij is lower in all arms, and the
dose is considered promising only in arms 2 and 3. Hyperparameter Setting 3 may be chosen if the
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investigators place strong emphasis on type I error control. Note that under Setting 3, although
patient accrual in arm 1 is stopped after the first interim analysis, the interim data for arm 1 (1
responder out of 10 patients) are still included in the second interim and the final analyses, a benefit
of Bayesian modeling.
Table 2 presents the second trial example. At the first interim analysis, 0, 3, 6 and 4 responders
are observed in arms 1, 2, 3 and 4, respectively. The posterior probability of H1,ij is only 0.046 for
arm 1 under Setting 1. As a result, arm 1 is stopped for futility. We can see similar performance
of the MUCE design in the second trial example: Setting 2 has stronger borrowing strength than
Setting 1, and Setting 3 has strong type I error control. Notice that due to early stopping of arm
1 under all three settings, we did not simulate any additional data for arm 1 in the second and
final analysis. The arm is terminated after interim look 1 to avoid treating more patients in this
potentially non-promising arm. Under Setting 3, arm 2 is also terminated after interim look 1. At
the end of the trial, the posterior probabilities of H1,ij for arms 2, 3 and 4 are over the efficacy
threshold φ2 = 0.9 under Settings 1 and 2. For Setting 3, only arms 3 and 4 are declared promising
due to the strong type I error control.
Table 2: Trial example II under the MUCE design. “Est. p” denotes the estimated response rate,
and “Prob. H1” denotes the posterior probability of the alternative hypothesis. The bold values
indicate the arms that are declared promising at the final analysis. The values in square brackets
indicate the arms that are stopped early due to futility. The values in parentheses indicate that the
interim data are carried forward for the subsequent analyses after the arms are stopped early.
Interim 1 Interim 2 Final Analysis
arm 1 2 3 4 1 2 3 4 1 2 3 4
n 10 10 10 10 10 20 20 20 10 29 29 29
y 0 3 6 4 0 6 10 8 0 9 14 11
y/n 0.0 0.3 0.6 0.4 0.0 0.3 0.5 0.4 0.00 0.31 0.48 0.38
Est. p
Set. 1 [0.002] 0.286 0.574 0.371 (0.000) 0.295 0.484 0.385 (0.004) 0.303 0.471 0.369
Set. 2 [0.003] 0.298 0.572 0.382 (0.001) 0.299 0.484 0.386 (0.006) 0.307 0.473 0.369
Set. 3 [0.000] [0.171] 0.397 0.220 (0.000) (0.235) 0.464 0.343 (0.000) (0.272) 0.470 0.353
Prob. H1
Set. 1 [0.069] 0.800 0.996 0.918 (0.059) 0.887 0.999 0.980 (0.084) 0.936 0.999 0.988
Set. 2 [0.184] 0.840 0.996 0.940 (0.153) 0.910 0.998 0.983 (0.229) 0.956 1.000 0.992
Set. 3 [0.004] [0.233] 0.620 0.366 (0.010) (0.550) 0.941 0.823 (0.003) (0.749) 0.996 0.924
We can also observe the effect of borrowing strength across arms by comparing the two trial
examples. For example, arm 3 in trial example I and arm 4 in trial example II have exactly the
same observed data (29 patients in total with 11 responders), while inference about H1,ij for these
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two arms is slightly different in the two trial examples. This is because such inference is affected
by the observed data in the other arms, which are different between the two trials.
4.2 Simulation 1: One Dose and Multiple Indications
We conduct extensive simulations to examine the operating characteristics of the proposed MUCE
design. In the first simulation study, we aim to benchmark the performance of MUCE against the
Simon’s two-stage design in terms of frequentist power, type I error rate, and average sample size.
We also include the BBHM, EXNEX and CBHM designs in the comparison. For a fair comparison,
we only consider one dose and four indications (i.e., J = 1 and I = 4), since BBHM, EXNEX and
CBHM are developed for basket trials rather than expansion cohort trials with two factors: doses
and indications.
We consider five different scenarios, shown in Table 3. We assume the reference response rate is
pii0 = 0.2 for all indications. We also set the target response rate pii1 = 0.35, which is required for
implementing the Simon’s two-stage, BBHM, EXNEX and CBHM designs. Under each scenario,
patient responses are generated according to the true response rates. The first scenario is a global
null scenario, in which all arms are non-promising having a response rate of 0.2. The second scenario
is a global alternative scenario with all arms promising having a response rate of 0.35. Scenarios
3–5 are mixed scenarios, with different numbers of promising and non-promising arms.
Table 3: True response rates of the four arms (indications) under the five scenarios in Simulation
1. The bold values mark the promising arms.
Scenario arm 1 arm 2 arm 3 arm 4
1 0.2 0.2 0.2 0.2
2 0.35 0.35 0.35 0.35
3 0.2 0.2 0.35 0.45
4 0.2 0.35 0.35 0.45
5 0.2 0.2 0.2 0.35
The Simon’s two-stage design with a prespecified type I error rate of 0.1 and a type II error
rate of 0.3 is given by the following: for each arm, treat 13 patients in the first stage. If ≤ 2
patients respond, stop the arm early; otherwise, treat additional 16 patients in the second stage
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(29 patients in total), and declare the arm promising if > 8 patients respond in total. To match
the maximum sample size of the Simon’s two-stage design, the maximum sample sizes for MUCE,
BBHM, EXNEX and CBHM are also set at 29 for every arm. Two interim looks for futility
stopping are conducted after 10 and 20 patient outcomes are observed in every arm for these four
Bayesian designs. The MUCE design is implemented under hyperparameter Setting 1 (see Section
4.1). The futility stopping boundary and the efficacy thresholds are chosen as φMUCE1 = 0.25 and
φMUCE2 = 0.924, respectively. The BBHM, EXNEX and CBHM designs are implemented under the
default hyperparameter settings recommended in the corresponding publications. The futility and
efficacy thresholds for BBHM, EXNEX and CBHM are set at φBBHM1 = φ
EXNEX
1 = φ
CBHM
1 = 0.08,
φBBHM2 = 0.879, φ
EXNEX
2 = 0.950 and φ
CBHM
2 = 0.957, respectively. These thresholds are chosen
such that (i) all designs yield approximately the same average sample size (≈ 21) under the global
null scenario (Scenario 1), and (ii) all Bayesian designs have the same family-wise type I error rate
(FWER) (= 0.15) under the global null scenario. Here, a family-wise type I error refers to a decision
in which at least one non-promising arm is falsely declared to be promising (i.e., at least one true
null hypothesis is rejected). The purpose of calibrating the threshold values is to benchmark the
comparison among different designs.
We simulate 1,000 trials under each scenario (Table 3) for each design. We record (i) the
percentage of trials in which an arm is declared promising. This is the type I error rate if the arm
is actually non-promising, or the power if the arm is truly promising. In addition to (i), we also
record (ii) the percentage of trials in which any non-promising arm is falsely declared promising,
i.e., the FWER, and (iii) the average sample size. The simulation results are shown in Figure 3.
In Scenario 1, although the arm-wise type I error rate of the Simon’s two-stage design is controlled
at 0.1, it has a FWER of 0.34. All the four Bayesian designs have arm-wise and family-wise type I
error rates lower than those of the Simon’s two-stage design. In Scenario 2, BBHM has the highest
power in all arms, followed by MUCE, Simon’s two-stage, CBHM and EXNEX. The high power
of BBHM in Scenario 2 is attributed to its strong borrowing of strength across arms, as shown in
Berry et al. (2013). In the mixed scenarios (Scenarios 3–5), the Simon’s two-stage design is able
to control the type I error rates for the non-promising arms at 0.1, because inference for each arm
is conducted separately. The BBHM design has elevated type I error rates in the non-promising
arms due to its strong borrowing behavior. We can also observe some type I error inflation for the
18
Figure 3: Comparison of power, type I error rate (left panel), and average sample size (right panel)
of the Simon’s two-stage, BBHM, EXNEX, CBHM, and MUCE designs under the five scenarios in
Simulation 1 (all with one dose level and four indications).
MUCE design, but such inflation is less extreme compared to the BBHM design and is considered
reasonable. Given that MUCE is not designed for basket trials, its performance exhibited in this
simulation seems satisfactory. In summary, MUCE is able to
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1. Control arm-wise and family-wise type I error rates under the global null scenario,
2. Exhibit desirable power under the global alternative scenario, and
3. Strike a good balance between type I error rate and power under the mixed scenarios. That
is, MUCE shows sufficient power in selecting the promising arms without greatly inflating the
type I error rate in selecting the non-promising arms.
The average sample sizes of the five designs are also reported in Figure 3, which are generally similar,
although the Simon’s two-stage design has slightly lower average sample sizes in some cases.
4.3 Simulation 2: Multiple Doses and Multiple Indications
In the second simulation study, we consider the motivating phase 1b multiple expansion cohort trial
example described in Section 1. Suppose three doses are graduated from phase 1a dose-escalation
to phase 1b expansion cohort, and four indications are of interest (i.e., J = 3 and I = 4). As a
result, 12 different dose-indication arms are available for expansion. The trial budget only allows
a total sample size of 120 patients with 10 patients per arm. We conduct simulation to examine
the frequentist operating characteristics as part of the initial new drug (IND) application to the
regulatory agency.
We consider six scenarios (Table 4) that specify the true response rates of the 12 arms. We
assume the reference response rate is pii0 = 0.2 for all the four indications. The first scenario
is a global null scenario with all arms non-promising having a response rate of 0.2. The second
scenario is a global alternative scenario with all arms promising having a response rate of 0.5. This
value is considered clinically beneficial to patients, and an arm exhibiting such a response rate
deserves further clinical development. Scenario 3 is also a global alternative scenario, in which all
the arms have response rates higher than 0.2 but ranged from 0.3 to 0.5. Scenarios 4–6 are mixed
scenarios with promising and non-promising arms. The promising arms in Scenarios 4 and 6 have a
response rate of 0.5 regardless of the dose, and the promising arms in Scenario 5 show an increasing
dose-response trend.
We assess the performance of the MUCE design under the default hyperparameter Setting 1 and
compare it with that of the BBHM, EXNEX and CBHM designs. The Simon’s two-stage design
is not considered here since it will lead to unacceptable FWER with 12 arms. We simulate 1,000
20
Table 4: True response rates of the twelve arms under the six scenarios in Simulation 2. The bold
values mark the promising arms.
Scenario dose level indication 1 indication 2 indication 3 indication 4
1
1 0.2 0.2 0.2 0.2
2 0.2 0.2 0.2 0.2
3 0.2 0.2 0.2 0.2
2
1 0.5 0.5 0.5 0.5
2 0.5 0.5 0.5 0.5
3 0.5 0.5 0.5 0.5
3
1 0.3 0.3 0.3 0.3
2 0.4 0.4 0.4 0.4
3 0.5 0.5 0.5 0.5
4
1 0.5 0.5 0.2 0.2
2 0.5 0.5 0.2 0.2
3 0.5 0.5 0.2 0.2
5
1 0.3 0.3 0.2 0.2
2 0.4 0.4 0.2 0.2
3 0.5 0.5 0.2 0.2
6
1 0.2 0.2 0.2 0.2
2 0.2 0.2 0.2 0.2
3 0.5 0.5 0.2 0.2
trials under each scenario (Table 4) for each design. With 10 patients per arm, no interim look
is implemented for all designs. Therefore, we do not need to specify the target response rate for
BBHM, EXNEX and CBHM, which is only used for interim futility stopping. For a fair comparison,
the efficacy thresholds φ2 for these four methods are calibrated to generate an identical FWER of
0.1 under Scenario 1 (global null). We obtain φMUCE2 = 0.988, φ
BBHM
2 = 0.948, φ
EXNEX
2 = 0.976 and
φCBHM2 = 0.989.
Figure 4 shows the power, arm-wise, and family-wise type I error rates of the different designs
under the six scenarios. In Scenario 1, all designs have the same FWER of 0.1 because of the
threshold calibration. In Scenarios 2 and 3, BBHM has the highest power to detect the promising
arms, followed by MUCE ≥ EXNEX > CBHM. This is expected, as BBHM has the highest degree
of borrowing, which allows it to perform better in the global alternative scenarios. In the mixed
scenarios (Scenarios 4–6), although BBHM still has the highest power for detecting the promising
arms, it shows inflated arm-wise and family-wise type I error rates. Furthermore, MUCE generally
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Figure 4: Comparison of power and arm-wise and family-wise type I error rates of the BBHM,
EXNEX, CBHM, and MUCE designs under the six scenarios in Simulation 2 (all with three dose
levels and four indications).
has better power and type I error control compared to EXNEX. Lastly, CBHM has the best type I
error control but lacks sufficient power to detect the promising arms. The reason why MUCE has
both decent power and type I error control is that it exploits the two-way expansion data structure
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and employs a latent probit model that allows different degrees of borrowing across doses and
indications. In contrast, BBHM, EXNEX and CBHM only consider one-dimensional information
borrowing.
4.4 Sensitivity Analysis and Multiplicity Control
In Section 4.1, we have demonstrated the behavior of the MUCE design under three hyperparameter
settings through two trial examples. In this section, we conduct sensitivity analysis to assess the
frequentist operating characteristics of MUCE under more hyperparameter settings and investigate
the effect of different hyperparameters. In addition to hyperparameter Settings 1–3 in Section 4.1,
we consider two more hyperparameter settings:
4. Setting 4: Same as Setting 1 except σ2ξ0 = σ
2
η0
= 0.12;
5. Setting 5: Same as Setting 1 except µξ0 = −3.
Setting 4 imposes weaker borrowing across arms than Setting 1, as it decreases the correlation of Zij
across arms (see Equation 6). Setting 5 provides weaker multiplicity control compared to Setting
3, although it still has stronger multiplicity control than Setting 1.
We consider simulation Scenarios 1–3 in Table 3 with one dose level and four indications. For
each scenario, we simulate 1,000 trials with the MUCE design under each hyperparameter setting.
Again, we set the maximum sample size for each arm at 29. For simplicity, we do not implement
interim looks for futility stopping during the trial. At the end of the trial, the threshold for declaring
treatment efficacy is φ2 = 0.95 for every hyperparameter setting.
The frequentist type I error rates and powers of MUCE under different hyperparameter settings
are reported in Figure 5. The results using the Simon’s two-stage design are also included in Figure
5 as a benchmark. The FWERs of MUCE under Settings 1, 2 and 4 are around 0.15 in Scenario
1, which are smaller than that of the Simon’s two-stage design. The two settings with stronger
multiplicity control, Settings 3 and 5, lead to much lower FWERs in Scenario 1. In Scenario 2, the
power ordering of Settings 1, 2 and 4 is Setting 2 > Setting 1 > Setting 4, which means that the
power in the global alternative scenario increases as the strength of borrowing increases. However,
the ordering of type I error rate in Scenario 3 among Settings 1, 2 and 4 is also Setting 2 > Setting
1 > Setting 4, meaning that strong borrowing strength leads to inflation of the type I error rate in
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the mixed scenario. Because of the multiplicity control, the type I error rates are well controlled
under Settings 3 and 5, but the powers under Settings 3 and 5 are also lower than those under the
other settings in both Scenarios 2 and 3.
Figure 5: Comparison of operating characteristics of the MUCE design under five different hyper-
parameter settings. The results are benchmarked with the Simon’s two-stage design.
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5 Discussion
We have proposed the MUCE design, which is a new Bayesian design for phase 1b multiple expansion
cohort trials. We take a formal Bayesian hypothesis testing approach to decide which dose-indication
combinations are promising for further investigation. Priors on the null and alternative hypotheses
are constructed, which lead to inference directly based on conditional (posterior) probabilities of
the hypotheses. To adaptively borrow information across arms, we build a latent probit model that
allows different degrees of borrowing across doses and indications. Through simulation studies, we
have shown that the MUCE design has desirable operating characteristics and compares favorably
to existing designs for multiple expansion cohort trials. We have also shown that the degree of
borrowing and multiplicity control can be adjusted through intuitive hyperparameter tuning.
Elicitation of the prior hyperparameters in the MUCE design can be discussed with the clinical
team based on the following two considerations. First, how strongly the team prefers to borrow
information across doses. This can be realized by increasing (or decreasing) the variances of ξi and
ηj’s, which lead to larger (or smaller) correlations of the latent probit scores. Second, how strongly
the team prefers to control the type I error rate in the presence of multiple tests. This can be
realized by assigning a more negative mean value for µξ0 and µη0 , as shown in Section 4.4.
Bayesian designs like MUCE may improve the efficiency of multi-arm trials by borrowing infor-
mation across arms, which can ideally lead to improved power to detect a treatment effect with
a reduced sample size. We note that borrowing may result in inflated type I error rates for the
non-promising arms if only part of the arms are truly promising. In addition, multiplicity issues in
multiple expansion cohort trials should be of concern, since multiple decisions are made at the end
that would result in further development of multiple doses/indications of the drug. A type I error
would lead to future failures and waste of resources.
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